Rocket Lab's 55% Drop Is a Pricing Error, Not a Business Failure

Rocket Lab stock has lost 55% from its May peak near $151 to the $60s. The three near-term headwinds are easy to name: dilution fears from an $8 billion Iridium acquisition, roughly $780 million in insider selling, and a delayed Neutron rocket.

The only problem is none of those change the forward business case.

Rocket Lab grew revenue 52% year-over-year, carries a 36.6% gross margin, holds $2.13 billion in cash, and is about to acquire Iridium Communications — a business that generated $871.7 million in 2025 revenue and $495 million in OEBITDA at a 57% margin. The market is pricing a 52% growth company like it's running out of runway. The math says otherwise.

The Operating Engine Is Accelerating

Revenue isn't just growing — it's accelerating through the quarters. Q1 2026 hit $200 million. Q2 reached $234 million, a 62% year-over-year jump and a $34 million sequential increase. The company guided Q3 to $250–$265 million, above the Street estimate of $238.5 million. The growth isn't a one-off spike; it's a trajectory.

Backlog tells the second half of the story. At $2.36 billion — up 137% year-over-year — Rocket Lab has 90+ launches contracted across its Electron, HASTE, and Neutron vehicles. That backlog grew by more than $437 million in new contracts during Q2 alone, including a $397 million U.S. Space Force contract to build and launch Flatellite spacecraft for the SB-AMTI program and $160+ million in geostationary satellite contracts, Rocket Lab's first entry into GEO satellite production for the U.S. government.

Revenue composition is shifting toward higher-margin product work. Satellite manufacturing, components, and related systems brought $181.3 million in Q2 — nearly four times the $52.7 million from launch services. Gross profit grew 96% year-over-year, well ahead of revenue growth. The Q3 gross margin guidance of 29–31% looks like a step down from the trailing 36.6%, but Q3 absorbs heavier Neutron-related capex and Iridium integration costs. The margin structure is a capital-deployment problem, not a business-model problem.

The Iridium Deal Changes the Entire Math

Here's what the stock drop misunderstands. Iridium isn't a cash burn. It's the cash generator Rocket Lab has been building toward.

Iridium operates a global L-band satellite network serving 2.55 million active subscribers. In 2025 it generated $871.7 million in revenue and $495 million in OEBITDA at a 57% margin. Rocket Lab alone is forecast to lose roughly $24 million in 2027. Add Iridium's $495 million in OEBITDA to the combined entity, and the company flips from cash-burning to cash-generating — before any synergies from eliminating third-party launch costs for Iridium's constellation replenishment.

The strategic logic mirrors SpaceX's Starlink model: offset capital-intensive rocket development with high-margin, recurring satellite communications revenue. But where Starlink is still loss-making despite massive scale, Iridium is already profitable at 57% OEBITDA.

The dilution concern is real but bounded. Rocket Lab established an at-the-market equity program of up to $1.94 billion to fund the cash portion of the deal, alongside a $3.6 billion bridge loan from Deutsche Bank and Wells Fargo. At roughly 640 million shares outstanding, a full draw on the ATM program adds maybe 5% dilution. The stock portion of the Iridium consideration — set by an exchange ratio with a collar from $67.50 to $112.50 — adds more, but the $495 million in incoming OEBITDA makes the combined entity accretive to intrinsic value, not dilutive.

The deal closes mid-2027, subject to Iridium stockholder approval and regulatory clearance.

Neutron: Development Delay, Not Development Failure

Neutron is the hinge. A 43-meter, methane-fueled, partially reusable medium-lift vehicle targeting 13,000 kg to LEO at an estimated $50 million per launch — positioned as an alternative to SpaceX's Falcon 9 for satellite constellations and national security missions. A first-stage fuel tank rupture during January hydrostatic pressure testing pushed the debut from mid-2026 to late-2026. The pad delivery target remains Q4 2026, but a 2027 first flight is increasingly likely.

This is a development timeline, not a development failure. New rockets take longer than planned. SpaceX's Starship ran through multiple explosions before achieving orbit. What matters for Rocket Lab is that the Neutron pipeline is already booked: the $397 million Space Force SB-AMTI contract, a dedicated Kepler Communications constellation mission, the $160+ million in GEO satellite contracts, and half a dozen other customers. The backlog exists. The customers are contracted. The variable is when the vehicle flies, not whether it's needed.

Where the Valuation Lives

At $38.2 billion market cap and $35.9 billion enterprise value, Rocket Lab trades at roughly 50x its own trailing twelve-month sales. By standalone metrics, that's expensive for an unprofitable company burning $371 million in free cash flow. The forward P/E is negative. ROIC is -8.6%. The raw numbers look terrible if you look at them alone.

But the 50x multiple is on pre-Iridium Rocket Lab — $770 million in standalone annual revenue. The combined entity reports roughly $1.6 billion in TTM revenue ($770M Rocket Lab + $872M Iridium). The $35.9 billion enterprise value against that combined base is roughly 22x. Not cheap. But 22x combined revenue for a company adding $495 million in 57%-margin OEBITDA, sitting on $2.28 billion net cash, growing its standalone business 52%, and building a reusable medium-lift rocket pipeline is a different number than 50x standalone burn.

The market priced Rocket Lab at its $151 peak like a Starship alternative with Iridium revenue already flowing. It's priced the stock at $63 like a cash-burning startup with a delayed rocket. The actual company sits between both: a scaling revenue business with a pending transformation that's already contracted, funded, and on a known timeline.

The Risks Are Execution, Not Economics

Neutron slips past 2027, and the growth catalyst pushes back. The Iridium deal doesn't close, and the bridge debt hangs over the balance sheet without the offsetting cash flow. The equity raise dilutes more than expected if the share price stays depressed through 2027. These are live questions. They don't change the underlying economics — they change the timing.

The Close

The combined company trades at roughly 72x Iridium's $495 million OEBITDA. That's the number that carries the thesis. A mature satellite operator at 72x OEBITDA is not cheap. But this isn't a mature satellite operator — it's a vertically integrated space company adding a 52%-growth launch and manufacturing business, a Neutron pipeline with contracted customers, $2.28 billion net cash, and an Iridium network that's already profitable at 57% margin. If Neutron launches and the deal closes, the 72x multiple compounds on a revenue base that grows past $1.6 billion with both engines firing. If it doesn't, the number was always going to contract.

Cathie Wood bought $44.5 million of the dip. The purchase is a sentiment data point. The evidence is in the backlog, the margins, the cash, and the Iridium OEBITDA. At 72x the combined entity's existing OEBITDA, the stock prices in execution risk but not the revenue growth already contracted and the margin transformation already signed. The market got the direction right — this is a bet on timing. The question is whether the timing is Q4 2026, 2027, or something longer.